'Over 80 percent of the patients developed symptoms
after their first or second dose of the COVID-19 vaccine'
On average, patients developed rheumatic diseases 11 days after vaccine administration, according to the study. Seventy-five (over 27 percent) of these patients experienced total disease remission, and about 50 percent improved following treatment. Eight were admitted to intensive care, and two died from their symptoms.
"The short time span between COVID-19 vaccine administration and the onset of R-IMIDs suggests a cause-and-effect relationship," the authors wrote.
Rheumatic immune-mediated inflammatory diseases (R-IMIDs) involve inflammation that manifests in the joints, tendons, muscles, and bones due to an unknown cause.
The study, led by researchers from the National Health Service in the United Kingdom, examined 271 participants from 190 case studies published worldwide.